









Mercado
/
Acciones
/
nasdaq-amgn
/

Amgen Inc

AMGN

384.320USD

+16.520+4.49%

Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min

207.15BCap. mercado

26.81P/E TTM



Amgen Inc

384.320

+16.520+4.49%

Descripción general Finanzas Análisis Compañía

Descripción general

Finanzas

Análisis

Compañía

Más Datos de Amgen Inc Compañía

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Información de Amgen Inc



Símbolo de cotizaciónAMGN

Nombre de la empresaAmgen Inc

Fecha de salida a bolsaJun 17, 1983

Director ejecutivoBradway (Robert A)

Número de empleados28000

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 17

DirecciónOne Amgen Center Drive

CiudadTHOUSAND OAKS

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal91320-1799

Teléfono18054471000

Sitio Webhttps://www.amgen.com/

Símbolo de cotizaciónAMGN

Fecha de salida a bolsaJun 17, 1983

Director ejecutivoBradway (Robert A)

Ejecutivos de Amgen Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Robert A. (Bob) Bradway

Chairman of the Board, President, Chief Executive Officer

566.37K

+8478.00%

Mr. Esteban Santos

Executive Vice President - Operations

69.05K

+2051.00%

Mr. Murdo Gordon

Executive Vice President - Global Commercial Operations

34.82K

-6879.00%

Dr. Tyler Jacks

Independent Director

17.19K

+809.00%

Mr. Derek Miller

Senior Vice President - Human Resources

9.93K

+612.00%

Dr. Brian J. Druker, M.D.

Independent Director

7.57K

+809.00%

Dr. Wanda M. Austin, Ph.D.

Independent Director

7.35K

+809.00%

Ms. Rachna Khosla

Senior Vice President - Business Development

6.66K

-1116.00%

Ms. Nancy A. Grygiel

Senior Vice President, Chief Compliance Officer

6.04K

Dr. Michael V. Drake, M.D.

Independent Director

4.89K

+219.00%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Robert A. (Bob) Bradway

Chairman of the Board, President, Chief Executive Officer

566.37K

+8478.00%

Mr. Esteban Santos

Executive Vice President - Operations

69.05K

+2051.00%

Mr. Murdo Gordon

Executive Vice President - Global Commercial Operations

34.82K

-6879.00%

Dr. Tyler Jacks

Independent Director

17.19K

+809.00%

Mr. Derek Miller

Senior Vice President - Human Resources

9.93K

+612.00%

Dr. Brian J. Druker, M.D.

Independent Director

7.57K

+809.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

Other products

1.85B

19.39%

Prolia

1.14B

11.92%

Repatha

794.00M

8.31%

Otezla

585.00M

6.12%

Enbrel

580.00M

6.07%

Otro

4.61B

48.20%

Por regiónUSD

Nombre

Ganancia

Proporción

6.33B

66.28%

ROW

2.26B

23.67%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Other products

1.85B

19.39%

Prolia

1.14B

11.92%

Repatha

794.00M

8.31%

Otezla

585.00M

6.12%

Enbrel

580.00M

6.07%

Otro

4.61B

48.20%

Estadísticas de accionistas

Actualizado: sáb., 15 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

10.14%

State Street Investment Management (US)

5.44%

BlackRock Institutional Trust Company, N.A.

5.30%

Capital International Investors

3.56%

Capital World Investors

3.49%

Otro

72.07%

Accionistas

Proporción

The Vanguard Group, Inc.

10.14%

State Street Investment Management (US)

5.44%

BlackRock Institutional Trust Company, N.A.

5.30%

Capital International Investors

3.56%

Capital World Investors

3.49%

Otro

72.07%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

53.90%

Investment Advisor/Hedge Fund

19.04%

Research Firm

4.88%

Pension Fund

2.21%

Bank and Trust

1.95%

Sovereign Wealth Fund

1.18%

Insurance Company

0.63%

Hedge Fund

0.42%

Individual Investor

0.17%

Otro

15.63%

Participación institucional



Actualizado: lun., 8 de dic

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

4407

451.47M

85.20%

+63.91K

2025Q3

4486

451.61M

85.29%

-1.24M

2025Q2

4487

452.85M

84.91%

+2.52M

2025Q1

4500

450.78M

83.12%

+3.88M

2024Q4

4470

440.57M

82.15%

+6.55M

2024Q3

4290

435.41M

82.39%

-1.01M

2024Q2

4260

436.06M

82.34%

+1.04M

2024Q1

4169

435.45M

81.98%

-3.93M

2023Q4

4130

433.32M

81.14%

+5.55M

2023Q3

3960

428.67M

80.98%

-560.79K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

53.62M

9.96%

-236.61K

-0.44%

Sep 30, 2025

State Street Investment Management (US)

29.30M

5.44%

-52.93K

-0.18%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

28.53M

5.3%

-304.25K

-1.06%

Sep 30, 2025

Capital International Investors

19.19M

3.56%

+282.22K

+1.49%

Sep 30, 2025

Capital World Investors

18.80M

3.49%

+1.94M

+11.48%

Sep 30, 2025

Charles Schwab Investment Management, Inc.

13.55M

2.52%

+656.93K

+5.10%

Sep 30, 2025

Geode Capital Management, L.L.C.

13.27M

2.46%

+248.90K

+1.91%

Sep 30, 2025

Invesco Capital Management (QQQ Trust)

12.08M

2.24%

+795.62K

+7.05%

Dec 31, 2025

PRIMECAP Management Company

9.71M

1.8%

-924.10K

-8.69%

Sep 30, 2025

Morgan Stanley Smith Barney LLC

8.89M

1.65%

+77.14K

+0.87%

Sep 30, 2025

ETFs relacionados



Actualizado: lun., 1 de dic

Nombre

Proporción

VanEck Biotech ETF

12.81%

FT Vest DJIA Dogs 10 Target Income ETF

12.23%

ProShares Ultra Nasdaq Biotechnology

8.42%

Invesco Nasdaq Biotechnology ETF

8.35%

Simplify Health Care ETF

7.93%

iShares Biotechnology ETF

7.08%

Invesco Dow Jones Industrial Average Dividend ETF

6.24%

Amplify Weight Loss Drug & Treatment ETF

5.87%

Invesco Pharmaceuticals ETF

5.05%

Invesco Biotechnology & Genome ETF

5.01%

VanEck Biotech ETF

Proporción12.81%

FT Vest DJIA Dogs 10 Target Income ETF

Proporción12.23%

ProShares Ultra Nasdaq Biotechnology

Proporción8.42%

Invesco Nasdaq Biotechnology ETF

Proporción8.35%

Simplify Health Care ETF

Proporción7.93%

iShares Biotechnology ETF

Proporción7.08%

Invesco Dow Jones Industrial Average Dividend ETF

Proporción6.24%

Amplify Weight Loss Drug & Treatment ETF

Proporción5.87%

Invesco Pharmaceuticals ETF

Proporción5.05%

Invesco Biotechnology & Genome ETF

Proporción5.01%

Dividendos



Un total de 17.60B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Dec 09, 2025

AMGN.NB Interim Cash Dividend of gross USD 2.52 paid on Mar 06, 2026 going ex on Feb 13, 2026

Feb 13, 2026

Mar 06, 2026

Feb 13, 2026

Oct 31, 2025

AMGN.NB Final Cash Dividend of gross USD 2.38 paid on Dec 12, 2025 going ex on Nov 21, 2025

Nov 21, 2025

Dec 12, 2025

Nov 21, 2025

Aug 01, 2025

AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Sep 12, 2025 going ex on Aug 22, 2025

Aug 22, 2025

Sep 12, 2025

Aug 22, 2025

Mar 04, 2025

AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Jun 06, 2025 going ex on May 16, 2025

May 16, 2025

Jun 06, 2025

May 16, 2025

Dec 10, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025

Feb 14, 2025

Mar 07, 2025

Feb 14, 2025

Oct 25, 2024

AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024

Nov 18, 2024

Dec 09, 2024

Nov 18, 2024

Aug 02, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Sep 06, 2024

Aug 16, 2024

Mar 06, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024

May 17, 2024

Jun 07, 2024

May 16, 2024

Dec 12, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024

Feb 16, 2024

Mar 07, 2024

Feb 15, 2024

Oct 24, 2023

AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023

Nov 17, 2023

Dec 08, 2023

Nov 16, 2023

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

